Amelioration of apomorphine adverse effects
US5994363A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 24, 1998 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Aug 24, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Symptoms of Parkinson's disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.